Can AI help pharmaceutical companies plan for drug shortages?

Merck KGaA, a Darmstadt, Germany-based pharmaceutical company, is hoping AI can improve its ability to predict drug shortages and plan accordingly.

The company says its current methods for forecasting supply and demand are 85% accurate, according to a new report from The Wall Street Journal, and it hopes AI can provide much more accuracy.

“The value is going to be that every single patient will receive the drug that he or she needs at the right moment,” said Alessandro DeLuca, CIO for Merck’s healthcare division, as quoted by the WSJ.

Merck is turning to TraceLink, a North Reading, Massachusetts-based supply chain company, to see if AI can make an impact. Merck plans on testing TraceLink’s cloud-based software platform later in 2019.  

Click the link below for the full story.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”